Ciclosporin A Preconditioning for Renal Artery Stenosis

Status Completed

Clinical Trial Summary

Renal artery stenosis is one the leading cause of secondary hypertension. Previous randomized controlled trials in humans have failed to demonstrate an improvement of renal function after stenosis dilation, probably because of a selection bias with more severe patients being excluded from randomization. Renal ischemia-reperfusion injuries have also not been taken into account. Indeed, reperfusion leads to a rapid renal blood flow recovery associated with renal ischemia-reperfusion injuries. Mitochondrial permeability transition pore (mPTP) is a key player in the occurrence of ischemia reperfusion injuries because its opening leads to mitochondria leakage and cell death. However, preconditioning whether pharmacological or ischemic can prevent mPTP opening and protect cells. Ciclosporin A can prolong mPTP closing during reperfusion and reduce renal and cardiac tissular lesions. Another mPTP blocker (Bendavia) has been associated with an improvement of renal blood flow (RBF) and glomerular filtration rate (GFR) after renal artery stenosis dilation at 6 weeks in pigs. Based on a recent study, dilation overall benefit could be secondary to an improvement of the contralateral kidney GFR and tissue oxygen content, requiring a single kidney evaluation of those renal functional parameters. The investigators previously demonstrated that dose and timing of ciclosporin A preconditioning is key to protect kidneys from ischemia-reperfusion injuries. Previous controlled trials that failed to demonstrate a benefit of ciclosporin A conditioning have used post conditioning on necrotic cells. Considering kidney ischemia-reperfusion injuries, preconditioning have led to more encouraging results compared to ciclosporin A post conditioning in animals. Therefore the investigators aim to conduct the first clinical study of ciclosporin A preconditioning for prevention of kidney ischemia-reperfusion injuries after renal artery stenosis dilation. Using renal functional imaging and the new PET-MRI (Positron Emission Tomography-Magnetic Resonance Imaging) combined device, the investigators will evaluate kidney perfusion, oxidative metabolism, glomerular filtration rate and oxygen content before and 3 months after renal artery stenosis dilation with or without a ciclosporin A preconditioning.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03382301
Study type	Interventional
Source	Hospices Civils de Lyon
Contact
Status	Completed
Phase	Phase 2
Start date	August 28, 2018
Completion date	June 18, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02528149` - Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study	N/A
Completed	`NCT02476526` - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease	Phase 4
Completed	`NCT00209391` - A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide	Phase 3
Completed	`NCT01673373` - Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension	N/A
Completed	`NCT02266394` - Hypoxia and Inflammatory Injury in Human Renovascular Hypertension	Phase 1
Recruiting	`NCT02388139` - Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (REN-ACS)	N/A
Active, not recruiting	`NCT01023373` - Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy	Phase 4
Recruiting	`NCT05603221` - Renal Perfusion Assessment in the Endovascular Treatment of Renal Artery Stenosis
Recruiting	`NCT03252639` - A Study of Using Parenchymal Blood Volume(PBV) for Endovascular Treatment of Renal Arterial Stenosis	N/A
Completed	`NCT00235157` - A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.	Phase 2
Completed	`NCT00001313` - Evaluation of Patients With Known or Suspected Heart Disease	N/A
Not yet recruiting	`NCT05612438` - RADIX 2 RENAL STENT Post-Market Retrospective Study
Withdrawn	`NCT03914157` - Ultrasound Wave Therapy for Post-stenotic Microvascular Remodeling	N/A
Completed	`NCT01128933` - Renal Fractional Flow Reserve in Renal Artery Stenting	N/A
Recruiting	`NCT03594786` - Impact of Supra-renal Fixation of EVAR on Hemodynamics of Renal Arteries	N/A
Completed	`NCT00885768` - Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization	Phase 3
Completed	`NCT04423458` - Evaluation of Advanced US Tools in Assessing Allograft Complications
Recruiting	`NCT02655341` - Hydration Status Assessment Through Body Composition Monitoring in Patients With Acute Myocardial Infarction	N/A
Completed	`NCT01576835` - Renal Artery Contrast-Free Trial	Phase 4
Completed	`NCT01057316` - Formula PTX Renal Stent Clinical Study	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ciclosporin A Preconditioning for Renal Artery Stenosis — CicloSAAR

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms